PA8479201A1 - Derivados del acido hidroxi-pipecolato hidroxamico - Google Patents

Derivados del acido hidroxi-pipecolato hidroxamico

Info

Publication number
PA8479201A1
PA8479201A1 PA19998479201A PA8479201A PA8479201A1 PA 8479201 A1 PA8479201 A1 PA 8479201A1 PA 19998479201 A PA19998479201 A PA 19998479201A PA 8479201 A PA8479201 A PA 8479201A PA 8479201 A1 PA8479201 A1 PA 8479201A1
Authority
PA
Panama
Prior art keywords
derivatives
pipecolate
hydroxamic
hydroxy acid
hydroxy
Prior art date
Application number
PA19998479201A
Other languages
English (en)
Inventor
Kim Francis Mcclure
Mark Carl Noe
Michael Anthony Letavic
Louis Stanley Chupak
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PA8479201A1 publication Critical patent/PA8479201A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A DERIVADOS DEL ÁCIDO HIDROXI-PIPECOLATO HIDROXÁMICO, A COMPOSICIONES FARMACEÚTICAS QUE COMPRENDEN TALES DERIVADOS Y AL USO DE TALES DERIVADOS EN EL TRATAMIENTO DE LA ARTRITIS, CÁNCER Y OTRAS ENFERMEDADES.
PA19998479201A 1998-08-12 1999-07-30 Derivados del acido hidroxi-pipecolato hidroxamico PA8479201A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9623298P 1998-08-12 1998-08-12

Publications (1)

Publication Number Publication Date
PA8479201A1 true PA8479201A1 (es) 2000-09-29

Family

ID=22256467

Family Applications (1)

Application Number Title Priority Date Filing Date
PA19998479201A PA8479201A1 (es) 1998-08-12 1999-07-30 Derivados del acido hidroxi-pipecolato hidroxamico

Country Status (43)

Country Link
US (2) US6329397B1 (es)
EP (1) EP1104403B1 (es)
JP (1) JP2002522528A (es)
KR (1) KR20010085374A (es)
CN (1) CN1316995A (es)
AP (1) AP2001002070A0 (es)
AR (1) AR019241A1 (es)
AT (1) ATE325791T1 (es)
AU (1) AU766366B2 (es)
BG (1) BG105323A (es)
BR (1) BR9912909A (es)
CA (1) CA2340202C (es)
CZ (1) CZ2001484A3 (es)
DE (1) DE69931266T2 (es)
DZ (1) DZ2870A1 (es)
EA (1) EA200100126A1 (es)
EE (1) EE200100086A (es)
ES (1) ES2263279T3 (es)
GE (1) GEP20033117B (es)
GT (1) GT199900131A (es)
HK (1) HK1040242A1 (es)
HN (1) HN1999000131A (es)
HR (1) HRP20010098A2 (es)
HU (1) HUP0103452A3 (es)
ID (1) ID27840A (es)
IL (1) IL141030A0 (es)
IS (1) IS5813A (es)
MA (1) MA26675A1 (es)
NO (1) NO20010686L (es)
NZ (1) NZ509296A (es)
OA (1) OA11594A (es)
PA (1) PA8479201A1 (es)
PE (1) PE20000951A1 (es)
PL (1) PL346041A1 (es)
SK (1) SK1872001A3 (es)
SV (1) SV1999000123A (es)
TN (1) TNSN99156A1 (es)
TR (1) TR200100474T2 (es)
UA (1) UA59453C2 (es)
UY (1) UY25993A1 (es)
WO (1) WO2000009485A1 (es)
YU (1) YU5201A (es)
ZA (1) ZA200101042B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6846799B1 (en) 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US7354894B2 (en) 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
CA2339140A1 (en) * 1998-08-31 2000-03-09 Merck & Co., Inc. Method of treating neurodegenerative diseases
US6509337B1 (en) * 1998-09-17 2003-01-21 Pfizer Inc. Arylsulfonyl Hydroxamic Acid derivatives as MMP and TNF inhibitors
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
EP1081137A1 (en) 1999-08-12 2001-03-07 Pfizer Products Inc. Selective inhibitors of aggrecanase in osteoarthritis treatment
EP1138680A1 (en) * 2000-03-29 2001-10-04 Pfizer Products Inc. Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
JP2001322977A (ja) * 2000-05-12 2001-11-20 Kotobuki Seiyaku Kk ピペコリン酸誘導体及びその製造方法並びにこれを含有する医薬組成物
JP2002105073A (ja) * 2000-09-27 2002-04-10 Shionogi & Co Ltd 新規マトリックスメタロプロテアーゼ阻害剤
DOP2002000333A (es) 2001-02-14 2002-09-30 Warner Lambert Co Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
DOP2002000332A (es) 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
EP1368323B1 (en) 2001-02-14 2010-06-30 Warner-Lambert Company LLC Pyrimidine matrix metalloproteinase inhibitors
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
CA2462442A1 (en) 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkyne matrix metalloproteinase inhibitors
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
MXPA04012932A (es) * 2002-06-26 2005-06-03 Japan Bioindustry Ass Nuevo derivado de azasugar y farmaco que lo contiene como ingrediente activo.
BR0312708A (pt) * 2002-07-17 2005-04-26 Warner Lambert Co Combinação de um inibidor alcina alostérico de metaloproteinase-13 de matriz com celecoxib ou valdecoxib
CA2491820A1 (en) * 2002-07-17 2004-01-22 Warner-Lambert Company Llc Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib
WO2004014892A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Monocyclic derivatives as matrix metalloproteinase inhibitors
AU2003249477A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors
WO2004014375A2 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
WO2004014378A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
BR0313724A (pt) 2002-08-13 2005-06-28 Warner Lambert Co Derivados de azaisoquinolina como inibidores de metaloproteinase de matriz
AU2003250470A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
PA8578101A1 (es) 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
AU2003253186A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
EP1553949B1 (en) 2002-08-13 2007-04-18 Warner-Lambert Company LLC Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
MXPA05001785A (es) 2002-08-13 2005-04-25 Warner Lambert Co Derivados de cromona como inhibidores de las metaloproteinasas de matriz.
CA2600954A1 (en) * 2005-03-22 2006-12-14 Innodia Inc. Compounds and compositions for use in the prevention and treatment of obesity and related syndromes
PL2105164T3 (pl) 2008-03-25 2011-05-31 Affectis Pharmaceuticals Ag Nowi antagoniści P2X7R i ich zastosowanie
PL2243772T3 (pl) 2009-04-14 2012-05-31 Affectis Pharmaceuticals Ag Nowi antagoniści p2x7r i ich zastosowanie
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
DE202016007195U1 (de) 2016-11-16 2017-11-17 Bernhard Kohler Strombegrenzende Schalteinrichtung
US20220008401A1 (en) * 2019-01-29 2022-01-13 Darsha Llc Compositions and methods for treating pulmonary disease with matrix metalloproteinase inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0821671B1 (en) * 1995-04-20 2000-12-27 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors
EP1095936B1 (en) * 1995-12-08 2004-11-24 Agouron Pharmaceuticals, Inc. Intermediates useful for the preparation of metallproteinase inhibitors
ATE226193T1 (de) * 1996-08-28 2002-11-15 Procter & Gamble Substituierte zyklische amine als metalloproteaseinhibitoren
BR9807815A (pt) * 1997-02-03 2000-03-08 Pfizer Prod Inc Derivados de ácido arilsulfonilamino-hidroxâmico
HUP0000657A3 (en) * 1997-02-11 2000-10-30 Pfizer N-arylsulfonyl-piperidine, -morpholine hydroxamic acid derivatives and pharmaceutical compositions containing them
WO1998050348A1 (en) * 1997-05-09 1998-11-12 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses

Also Published As

Publication number Publication date
MA26675A1 (fr) 2004-12-20
HRP20010098A2 (en) 2002-02-28
EP1104403B1 (en) 2006-05-10
US20030008901A1 (en) 2003-01-09
CA2340202C (en) 2006-02-07
EP1104403A1 (en) 2001-06-06
JP2002522528A (ja) 2002-07-23
GT199900131A (es) 2001-02-02
UA59453C2 (uk) 2003-09-15
IL141030A0 (en) 2002-02-10
DE69931266T2 (de) 2007-02-15
TR200100474T2 (tr) 2001-06-21
DE69931266D1 (en) 2006-06-14
ZA200101042B (en) 2002-10-07
US6329397B1 (en) 2001-12-11
DZ2870A1 (fr) 2003-12-15
GEP20033117B (en) 2003-11-25
HUP0103452A2 (hu) 2002-04-29
ES2263279T3 (es) 2006-12-01
BG105323A (en) 2001-10-31
CN1316995A (zh) 2001-10-10
AU4924799A (en) 2000-03-06
ATE325791T1 (de) 2006-06-15
NO20010686L (no) 2001-04-09
CZ2001484A3 (cs) 2002-05-15
SK1872001A3 (en) 2002-08-06
ID27840A (id) 2001-04-26
AP2001002070A0 (en) 2001-03-31
TNSN99156A1 (fr) 2005-11-10
EA200100126A1 (ru) 2001-08-27
NO20010686D0 (no) 2001-02-09
HN1999000131A (es) 2000-03-24
UY25993A1 (es) 2000-03-31
IS5813A (is) 2001-01-16
YU5201A (sh) 2003-07-07
HUP0103452A3 (en) 2002-10-28
PE20000951A1 (es) 2000-09-27
AR019241A1 (es) 2001-12-26
WO2000009485A1 (en) 2000-02-24
AU766366B2 (en) 2003-10-16
NZ509296A (en) 2003-10-31
HK1040242A1 (zh) 2002-05-31
SV1999000123A (es) 2000-07-06
CA2340202A1 (en) 2000-02-24
BR9912909A (pt) 2001-05-08
KR20010085374A (ko) 2001-09-07
OA11594A (en) 2004-07-11
EE200100086A (et) 2002-08-15
PL346041A1 (en) 2002-01-14

Similar Documents

Publication Publication Date Title
PA8479201A1 (es) Derivados del acido hidroxi-pipecolato hidroxamico
BR9906581A (pt) Processo para administração de taxano encapsulado em lipossomos
GT199900070A (es) Derivados de isotiazol, utiles como agentes anticancerosos.
AR020019A1 (es) Composicion farmaceutica para la prevencion o el tratamiento de cancer de mama
UY28213A1 (es) Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
BR0212611A (pt) Compostos de pirazolila substituìdos para o tratamento da inflamação
UY27943A1 (es) Composiciones y mctodos para tratar el crncer usando inmunoconjugados de anticuerpo para cd44 citotnxicos y agentes quimioterapcuticos
CL2008001813A1 (es) Compuestos derivados de quinolin-3-carbonitrilo sustituidos con piperazina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis, inflamacion, cancer entre otras (div. sol. 266-04).
MX9301929A (es) Derivados de pirimidina y procedimientos para su preparacion.
MX2023001997A (es) Compuestos biciclicos, composiciones y usos de los mismos.
AU8490901A (en) Urea compounds and methods of uses
BR0213424A (pt) Uso aperfeiçoado de composto antitumoral na terapia contra câncer
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
BRPI0410503A (pt) uso da ivermectina para a fabricação de uma composição farmacêutica tópica, composição tópica e uso da composição
TW200505483A (en) New medicament compositions based on anticholinergically-effective compounds and β-mimetics
BR0211801A (pt) Derivados de 7h-pirrolo[2,3-d]pirimidina
BR9608488A (pt) Uso de derivados da vitamina d4 no tratamento de câncer
UY26456A1 (es) Compuestos que fijan la estructura g-cuadruplex de los telomeros, triazinas de aplicación de dichos compuestos, la utilización de dichos compuestos como productos farmacéuticos y las asociaciones terapéuticas que los incluyen.
BR0115162A (pt) Tratamentos antitumorais eficazes
UA29466C2 (uk) Фармацевтична композиція з антипухлинною активністю
ECSP034518A (es) Nuevos retinoides para el tratamiento de enfisema
BRPI0409742A (pt) uso de um agente anti-angiogênico, em combinação com um inibidor da famìlia src de tirosina quinases não-receptoras, produto de combinação, e, composição farmacêutica
BR0314195A (pt) Derivados de piridina substituìda como agentes antitumorais
BR0108728A (pt) Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
TR200400228T4 (tr) Psöryazinin tedavisinde kullanılacak maddeler